TAK-279 Clinical Trials (2026): 12 Studies for Healthy Volunteers & Plaque Psoriasis

Hipa.ai Research · Source: ClinicalTrials.gov / AACT

Synced daily from ClinicalTrials.gov via AACT. Last sync: .

12 TAK-279 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 7 indications (including Healthy Volunteers & Plaque Psoriasis) and 4,780 total planned enrollment. 4 Phase 3 TAK-279 trials and 2 Phase 2 are listed. 1 TAK-279 clinical trial is actively recruiting at 23 U.S. sites across 14 states. Most recent activity: NCT06550076 (Aug 2029).

Where to Participate: All TAK-279 Trial Sites in the U.S. (23 sites across 14 states)

Every actively recruiting TAK-279trial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.

StateFacilityCityTrialMap
CAGastroIntestinal BioSciencesLos Angeles90067NCT06233461Map
CAUnited Medical DoctorsMurrieta92563NCT06233461Map
CAUCI HealthOrange92868NCT06233461Map
FLWest Central Gastroenterology, LLP, d/b/a/ Gastro FloridaClearwater33762NCT06233461Map
FLAuzmer ResearchLakeland33813NCT06233461Map
FLWellness Clinical ResearchMiami Lakes33016NCT06233461Map
FLGI PROS, Inc.Naples34102NCT06233461Map
FLUSF Health Morsani Center for Advanced HealthcareTampa33612NCT06233461Map
GAEmory University Hospital, The Emory ClinicAtlanta30322NCT06233461Map
GAAtlanta Center For Gastroenterology, P.C.Decatur30033NCT06233461Map
IAThe University of Iowa Hospitals & ClinicsIowa City52242NCT06233461Map
KYUniversity Of LouisvilleLouisville40202NCT06233461Map
MDWoodholme Gastroenterology AssociatesGlen Burnie21061NCT06233461Map
MOBVL Clinical ResearchLiberty64068NCT06233461Map
NVLas Vegas Medical ResearchLas Vegas89128NCT06233461Map
NYIcahn School of Medicine at Mount Sinai (ISMMS) - The Mount Sinai Hospital (MSH)New York10029NCT06233461Map
OHGreat Lakes Gastroenterology Research, LLCMentor44060NCT06233461Map
RIUniversity Gastroenterology ProvidenceProvidence02904NCT06233461Map
SCGastroenterology Associates, PAGreenville29615NCT06233461Map
TXNovel Research, LLCBellaire77401NCT06233461Map
TXSouthern Star Research Institute, LLCSan Antonio78229NCT06233461Map
TXTyler Research Institute, LLCTyler75701NCT06233461Map
WAUniversity of Washington Medical CenterSeattle98195NCT06233461Map

TAK-279 clinical trials at a glance: phase × recruitment status

Phaserecruitingactive not recruitingcompletedTotal
P166
P2112
P3224

Recruiting TAK-279 clinical trials (1)

Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).

NCT IDTitlePhaseIndicationEnrollmentStarted
NCT06233461A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's DiseaseP2Crohn's Disease268Mar 2024

TAK-279 clinical trials by indication

Healthy Volunteers (4)

NCTAcronymPhaseStatusTitle
NCT06111547P1completedA Study of TAK-279 in Healthy Chinese Adults
NCT06258265P1completedA Study of TAK-279 in Healthy Adults on the Effect on ECG Measurements
NCT06290050P1completedA Study of the Interaction of Other Drugs With TAK-279 in Healthy Adults
NCT05995249P1completedA Study of the Interaction of TAK-279 With Substances That Have an Impact on Metabolism in Healthy Adults

Plaque Psoriasis (3)

NCTAcronymPhaseStatusTitle
NCT06550076P3active not recruitingA Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis
NCT06108544P3completedA Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period
NCT06088043P3completedA Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment

Ulcerative Colitis (1)

NCTAcronymPhaseStatusTitle
NCT06254950P2active not recruitingA Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis

Generalized Pustular Psoriasis (1)

NCTAcronymPhaseStatusTitle
NCT06323356P3active not recruitingA Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

Crohn's Disease (1)

NCTAcronymPhaseStatusTitle
NCT06233461P2recruitingA Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

Renal Impairment (1)

NCTAcronymPhaseStatusTitle
NCT05992155P1completedA Study of TAK-279 in Adults With or Without Kidney Problems

Hepatic Impairment (1)

NCTAcronymPhaseStatusTitle
NCT05976321P1completedA Study of TAK-279 in Adults With or Without Liver Damage

All TAK-279 trials (12)

Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.

NCT IDAcronymTitlePhaseStatusEnrollmentSponsorStarted
NCT06550076A Study of TAK-279 in Participants With Moderate-to-Severe Plaque PsoriasisP3active not recruiting2,099TakedaSep 2024
NCT06254950A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative ColitisP2active not recruiting207TakedaMar 2024
NCT06233461A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's DiseaseP2recruiting268TakedaMar 2024
NCT06323356A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic PsoriasisP3active not recruiting18TakedaMar 2024
NCT06108544A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment PeriodP3completed1,108TakedaNov 2023
NCT06088043A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of TreatmentP3completed693TakedaNov 2023
NCT06111547A Study of TAK-279 in Healthy Chinese AdultsP1completed24TakedaJun 2024
NCT06258265A Study of TAK-279 in Healthy Adults on the Effect on ECG MeasurementsP1completed120TakedaApr 2024
NCT05992155A Study of TAK-279 in Adults With or Without Kidney ProblemsP1completed24TakedaSep 2023
NCT06290050A Study of the Interaction of Other Drugs With TAK-279 in Healthy AdultsP1completed20TakedaMar 2024
NCT05976321A Study of TAK-279 in Adults With or Without Liver DamageP1completed27TakedaSep 2023
NCT05995249A Study of the Interaction of TAK-279 With Substances That Have an Impact on Metabolism in Healthy AdultsP1completed172TakedaAug 2023

TAK-279 clinical trials: frequently asked questions

How many TAK-279 clinical trials are there?
12 TAK-279 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants. 8 are marked completed.
Are TAK-279 clinical trials recruiting in 2026?
Yes — 1 TAK-279 trial is actively recruiting in 2026, with 23 U.S. sites across 14 states. See the recruiting trials and the per-state site list further down this page.
What conditions is TAK-279 being studied for?
TAK-279 is being studied for Healthy Volunteers, Plaque Psoriasis, Generalized Pustular Psoriasis, Hepatic Impairment, Renal Impairment and 3 more. The trials are grouped by indication on this page.
What phase is TAK-279 in?
TAK-279 clinical trials span 4 Phase 3, 2 Phase 2, 6 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
Who sponsors TAK-279 clinical trials?
The lead sponsor across the most TAK-279 trials is Takeda. Each trial row links to the full study detail page including sponsor information.

Sources and methodology

Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming TAK-279as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.

Last refreshed .

Related pages on Hipa.ai: